Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses. This trial also showed that a vector-prime protein boost combined vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Eslamizar, Leila, Petrovas, Constantinos, Leggat, David J., Furr, Kathryn, Lifton, Michelle L., Levine, Gail, Ma, Steven, Fletez-Brant, Christopher, Hoyland, Wesley, Prabhakaran, Madhu, Narpala, Sandeep, Boswell, Kristin, Yamamoto, Takuya, Liao, Hua-Xin, Pickup, David, Ramsburg, Elizabeth, Sutherland, Laura, McDermott, Adrian, Roederer, Mario, Montefiori, David, Koup, Richard A., Haynes, Barton F., Letvin, Norman L., Santra, Sampa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835239/
https://www.ncbi.nlm.nih.gov/pubmed/33495459
http://dx.doi.org/10.1038/s41541-020-00277-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835239/
https://www.ncbi.nlm.nih.gov/pubmed/33495459
http://dx.doi.org/10.1038/s41541-020-00277-1

Ejemplares similares